
Overview
Biopsies of castration resistant prostate cancer metastases were subjected to whole genome sequencing (WGS), along with RNA-sequencing (RNA-Seq). The overarching goal of the study is to illuminate molecular mechanisms of acquired resistance to therapeutic agents, and particularly androgen signaling inhibitors, in the treatment of metastatic castration resistant prostate cancer (mCRPC). This study is made available on AWS via the NIH STRIDES Initiative.
Features and programs
Open Data Sponsorship Program
Pricing
This is a publicly available data set. No subscription is required.
How can we make this page better?
Legal
Content disclaimer
Delivery details
AWS Data Exchange (ADX)
AWS Data Exchange is a service that helps AWS easily share and manage data entitlements from other organizations at scale.
Open data resources
Available with or without an AWS account.
- How to use
- To access these resources, reference the Amazon Resource Name (ARN) using the AWS Command Line Interface (CLI). Learn more
- Description
- Whole Genome Sequencing, RNA Sequencing
- Resource type
- S3 bucket
- Amazon Resource Name (ARN)
- arn:aws:s3:::gdc-wcdt-mcrpc-phs001648-2-open
- AWS region
- us-east-1
- AWS CLI access (No AWS account required)
- aws s3 ls --no-sign-request s3://gdc-wcdt-mcrpc-phs001648-2-open/
Resources
Vendor resources
Support
How to cite
Genomic Characterization of Metastatic Castration Resistant Prostate Cancer was accessed on DATE from https://registry.opendata.aws/mcrpc .
License
NIH Genomic Data Sharing Policy: https://gdc.cancer.gov/access-data/data-access-policies